Oxford BioMedica plc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oxford BioMedica plc with three other
companies in this sector in the United Kingdom:
sales of £54.11 million [US$69.55 million]
of which 51%
was Drug Safety and medical information serv),
Circassia Pharmaceuticals PLC
(£48.30 million [US$62.08 million]
of which 57%
was operating-NIOX), and
GW Pharmaceuticals PLC
(£20.00 million [US$25.71 million]
of which 100%
was Novel Therapeutics).
During the year ended December of 2018, sales at
Oxford BioMedica plc were £66.78 million (US$85.83 million).
increase of 77.6%
versus 2017, when the company's sales were £37.59 million.
This was the fifth consecutive year of sales increases at Oxford BioMedica plc
(and since 2013, sales have increased a total of 1,142%).